LIXTE Biotechnology Sponsors Health Equity Summit Inspired by De La Soul Legacy

LIXTE Biotechnology Holdings is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event inspired by the music, legacy, and lived experiences of De La Soul and scheduled for Feb. 19 at Morehouse College in Atlanta. The Summit brings together leaders in health, culture, science, and community to advance health equity for Black men and families and is rooted in De La Soul’s song “Good Health,” written following the passing of founding member David Jolicoeur. Developed in collaboration with Blacksmith holdings, the program reflects De La Soul’s evolution from musical pioneers to wellness advocates and will feature discussions spanning cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness.

LIXT said the Summit aligns with its mission as a clinical-stage pharmaceutical company advancing cancer care through its first-in-class oncology compound LB-100 and its European research subsidiary, LIORA, while creating a space to connect scientific innovation with communities most impacted by health disparities. LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.

LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology - activation lethality - that is advancing a new treatment paradigm. LIXTE’s new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The sponsorship represents a strategic alignment between pharmaceutical innovation and community health initiatives, particularly addressing disparities that disproportionately affect Black communities. The Summit’s focus on comprehensive wellness—from physical conditions like cancer and heart disease to mental health and relational wellbeing—creates a holistic platform for dialogue that bridges medical research with cultural relevance.

This initiative matters because it represents a convergence of biotechnology investment with targeted health equity efforts, addressing systemic gaps in healthcare access and outcomes. By sponsoring an event rooted in cultural legacy and community leadership, LIXTE positions its scientific work within a broader social context, potentially increasing trust and engagement in underserved populations. The implications extend beyond a single event, suggesting a model for how pharmaceutical companies can contribute to public health beyond drug development alone. For communities facing higher rates of cancer and other health challenges, such partnerships may foster greater awareness, earlier intervention, and more inclusive research participation. The Summit’s invitation-only format emphasizes curated expertise and meaningful dialogue, while its location at Morehouse College underscores the importance of historically Black institutions in advancing health equity. As clinical trials for LB-100 progress, this community engagement could inform more patient-centered approaches to oncology care and drug development.